Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: Six years of experience

被引:0
|
作者
Huland, E [1 ]
Heinzer, H [1 ]
Mir, TS [1 ]
Huland, H [1 ]
机构
[1] Univ Hamburg, Clin Eppendorf, Dept Urol, D-20246 Hamburg, Germany
关键词
inhalation therapy; interferon-alpha; interleukin-2; pulmonary metastases; quality of life; renal cell carcinoma;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Patients with advanced metastatic renal cell carcinoma often cannot or do not want to tolerate high-dose systemic interleukin-2 (IL-2) therapy and the toxicity associated with it. To reduce toxicity and still maintain or even increase effectiveness, we developed a method to deliver IL-2 locally for the treatment of pulmonary and mediastinal metastases in metastatic renal cell carcinoma patients. PATIENTS AND METHODS We report here 6 years of experience treating 116 metastatic renal cell carcinoma patients who had pulmonary or mediastinal metastases with inhaled IL-2. We have utilized three different IL-2 preparations (natural human IL-2 purified from the supernatants of mitogen-activated peripheral blood lymphocytes, glycosylated recombinant IL-2 produced by Chinese hamster ovary cells, and non-glycosylated recombinant IL-2 produced by bacteria), AU protocols used high-dose inhalation of IL-2, either exclusively (11%), with coadministration of low-dose systemic IL-2 (33%), or with coadministration of low-dose systemic IL-2 and interferon-alpha (56%). RESULTS Maximal toxicity per total treatment rime was mild (median treatment time, 7.2 months); there was a low incidence (16%) of World Health Organization grade 3 toxicity. Toxicity associated with exclusive inhalation of IL-2 was local and consisted mainly of cough. Thus, patients who could not tolerate high-dose systemic IL-2 were able to tolerate inhalation IL-2 therapy. Progressive pulmonary metastases responded in 15% of patients for a median of 15.5 months (rang, 4.1-33 months) and were stabilized in 55% of patients for a median of 6.6 months (range, 3-51.7 months). The overall response rate was 16%; disease was stabilized in 49% of patients and disease progressed in 35% of patients. The overall median response duration was 3.6 months. Median survival was 11.8 months (range, 1.7-68.8 months); expected survival according to risk analysis was 5.3 months. CONCLUSIONS Inhalation of IL-2 is a nontoxic and effective treatment for patients with progressive pulmonary and mediastinal metastases. Inhaled IL-2 effectively prevented progress of pulmonary metastases in 70% of patients. Furthermore, patients could be treated as outpatients and remain employed. Local administration of IL-2 increases therapeutic effectiveness with little or no toxicity.
引用
下载
收藏
页码:S98 / S105
页数:8
相关论文
共 50 条
  • [21] TREATMENT OF METASTATIC MELANOMA AND RENAL-CELL CARCINOMA WITH INTERLEUKIN-2
    MANSON, LA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (17): : 1327 - 1327
  • [22] Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma
    Donskov, Frede
    DANISH MEDICAL BULLETIN, 2007, 54 (04) : 249 - 265
  • [23] INTERLEUKIN-2 AND INTERFERON-ALPHA-2A OUTPATIENT THERAPY FOR METASTATIC RENAL-CELL CARCINOMA
    LIPTON, A
    HARVEY, H
    GIVANT, E
    HOPPER, K
    LAWLER, J
    MATTHEWS, Y
    HIRSH, M
    ZEFFREN, J
    JOURNAL OF IMMUNOTHERAPY, 1993, 13 (02) : 122 - 129
  • [24] High-Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma and Metastatic Melanoma: Still the Standard
    Dutcher, Janice P.
    ONCOLOGY-NEW YORK, 2011, 25 (05): : 427 - 428
  • [25] Review of inhaled recombinant interleukin-2 (rIL-2) in patients with renal cell carcinoma with pulmonary metastases.
    Michelson, G
    Esteban, E
    Garcia-Giron, C
    Jimenez-Lacave, A
    Canelas, A
    Maroto, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 441S - 441S
  • [26] High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: The University of Chicago experience
    Shulman, KL
    Stadler, WM
    Vogelzang, NJ
    UROLOGY, 1996, 47 (02) : 194 - 197
  • [27] Complete remission of pulmonary metastasized renal cell carcinoma after inhalative interleukin-2 therapy
    Rohrmann, K
    Schleypen, J
    Adam, C
    Hofstetter, A
    Siebels, M
    UROLOGE A, 2004, 43 (10): : 1271 - 1274
  • [28] Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2
    Merimsky, O
    Gez, E
    Weitzen, R
    Nehushtan, H
    Rubinov, R
    Hayat, H
    Peretz, T
    Ben-Shahar, M
    Biran, H
    Katsenelson, R
    Mermershtein, V
    Loven, D
    Karminsky, N
    Neumann, A
    Matcejevsky, D
    Inbar, M
    ANNALS OF ONCOLOGY, 2004, 15 (04) : 610 - 612
  • [29] SURGICAL RESECTION FOLLOWING INTERLEUKIN-2 THERAPY FOR METASTATIC RENAL-CELL CARCINOMA PROLONGS REMISSION
    KIM, B
    LOUIE, AC
    ARCHIVES OF SURGERY, 1992, 127 (11) : 1343 - 1349
  • [30] Treatment Outcome of Low-dose Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma
    Takezawa, Yuta
    Izumi, Kouji
    Shimura, Yusuke
    Aerken, Maolake
    Natsagdorji, Ariunbold
    Iijima, Masashi
    Shigehara, Kazuyoshi
    Nohara, Takahiro
    Narimoto, Kazutaka
    Kadono, Yoshifumi
    Kitagawa, Yasuhide
    Konaka, Hiroyuki
    Mizokami, Atsushi
    ANTICANCER RESEARCH, 2016, 36 (09) : 4961 - 4964